Tachibana provided third quarter 2025 guidance of total company revenue in the range of $12 million to $14 million and pharma test/services revenue in the range of $11 million to $13 million.

The company raised 2025 total revenue guidance to $310 million–$320 million. Stokes explained that “our normalized revenue growth range in 2025 would be approximately 21% to 26%” when excluding ...

Faust provided Q3 2025 guidance: "We expect revenue between $1.875 billion and $1.975 billion, representing growth of 27% sequentially at the midpoint... Gross margin is expected to be between 13% and ...

Paul J. Diaz, President and Chief Executive Officer: "As we executed strategic initiatives to accelerate growth during the recent stages of the COVID-19 pandemic, we saw a significant recovery in test ...